Gapping up
In reaction to strong earnings/guidance: RUBI +19.2%, GIMO +14.8%, MXWL +11.8%, (Maxwell Tech announces development agreement with Corning (GLW) to advance Ultracapacitor technologies ), KLAC +11.7%, BJRI +11.5%, QLIK +9.7%, FLIR +9.7%, EW +9.3%, N +6.7%, SHPG +4.5%, GHL +4.4%, FII +4%, PFPT +3.6%, BBGI +3.6%, MSFT +2.7%, POL +2.4%, LEA +2.3%, CB +2%, ALGN +1.9%, PACB +1.8%, IM +1.8%, LPNT +1.8%, LYB +1.6%, IDXX +1.5%, UPS +1.5%, WRI +1.3%, NCR +1%, (light volume), LOGM +0.9%, PFG +0.8%
M&A news: DRIV +48.2% (to be acquired by investor group led by Siris Capital Group for $26.00 per share in cash), RP +6.1% (FT indicated apprached by buyers), CQB +0.7% (Board considered the revised $14.50 offer from Cutrale/Safra and determined to reaffirm its recommendation of the ChiquitaFyffes (FYFFF) merger)
Select Ebola related names showing strength: APT +22.4%, LAKE +17.4%, IBIO +14.7%, TKMR +4.8%, INO +3.1%, NLNK +2.4%, SRPT +2.2%, BCRX +2.1%.
Other news: VTAE +35.8% (positive top-line results achieved from Two Phase 1 clinical trials of BACE inhibitor BI1181181/VTP-37948 in Alzheimer's Disease ), RP +6.1% (seeing reports that multiple buyers are interested in the company), LGF +4.6% ( Alibaba (BABA) considering purchase 37.4% stake in LGF), MNOV +4% (CDC supports recruitment for MediciNova's Clinical Trial of MN-166 in ALS), PFPT +3.6% (signed a definitive agreement to acquire Nexgate for $35 mln in cash), ARIA +2.8% (European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with ARIA's Iclusig), EMES +2.5% (declared a cash distribution of $1.38 for the third quarter of 2014, an 18% increase over the second quarter 2014 distribution of $1.17 per unit), VOD +2.2% (still checking), LJPC +1.9% (announces data presentation at the American Society of Nephrology Kidney Week; short term therapy with the galectin-3 inhibitor, GCS-100 at 1.5 mg/m2, resulted in small but significant improvement in Egfr), SD +1.7% (announced that its wholly-owned subsidiary MidCon Midstream, LP has filed a registration statement with the SEC relating to its proposed IPO), PFE +1.5% (declares $0.26 fourth-quarter 2014 dividend and Board authorizes new $11 bln share repurchase program)
Analyst comments: RMD +2.7% (upgraded to Outperform from Mkt Perform at William Blair), FMS +1.4% (upgraded to Buy from Hold at Berenberg), BDN +0.9% (upgraded to Buy from Hold at Stifel), DLR +0.7% (upgraded to Mkt Perform from Underperform at Cowen)
In reaction to strong earnings/guidance: RUBI +19.2%, GIMO +14.8%, MXWL +11.8%, (Maxwell Tech announces development agreement with Corning (GLW) to advance Ultracapacitor technologies ), KLAC +11.7%, BJRI +11.5%, QLIK +9.7%, FLIR +9.7%, EW +9.3%, N +6.7%, SHPG +4.5%, GHL +4.4%, FII +4%, PFPT +3.6%, BBGI +3.6%, MSFT +2.7%, POL +2.4%, LEA +2.3%, CB +2%, ALGN +1.9%, PACB +1.8%, IM +1.8%, LPNT +1.8%, LYB +1.6%, IDXX +1.5%, UPS +1.5%, WRI +1.3%, NCR +1%, (light volume), LOGM +0.9%, PFG +0.8%
M&A news: DRIV +48.2% (to be acquired by investor group led by Siris Capital Group for $26.00 per share in cash), RP +6.1% (FT indicated apprached by buyers), CQB +0.7% (Board considered the revised $14.50 offer from Cutrale/Safra and determined to reaffirm its recommendation of the ChiquitaFyffes (FYFFF) merger)
Select Ebola related names showing strength: APT +22.4%, LAKE +17.4%, IBIO +14.7%, TKMR +4.8%, INO +3.1%, NLNK +2.4%, SRPT +2.2%, BCRX +2.1%.
Other news: VTAE +35.8% (positive top-line results achieved from Two Phase 1 clinical trials of BACE inhibitor BI1181181/VTP-37948 in Alzheimer's Disease ), RP +6.1% (seeing reports that multiple buyers are interested in the company), LGF +4.6% ( Alibaba (BABA) considering purchase 37.4% stake in LGF), MNOV +4% (CDC supports recruitment for MediciNova's Clinical Trial of MN-166 in ALS), PFPT +3.6% (signed a definitive agreement to acquire Nexgate for $35 mln in cash), ARIA +2.8% (European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with ARIA's Iclusig), EMES +2.5% (declared a cash distribution of $1.38 for the third quarter of 2014, an 18% increase over the second quarter 2014 distribution of $1.17 per unit), VOD +2.2% (still checking), LJPC +1.9% (announces data presentation at the American Society of Nephrology Kidney Week; short term therapy with the galectin-3 inhibitor, GCS-100 at 1.5 mg/m2, resulted in small but significant improvement in Egfr), SD +1.7% (announced that its wholly-owned subsidiary MidCon Midstream, LP has filed a registration statement with the SEC relating to its proposed IPO), PFE +1.5% (declares $0.26 fourth-quarter 2014 dividend and Board authorizes new $11 bln share repurchase program)
Analyst comments: RMD +2.7% (upgraded to Outperform from Mkt Perform at William Blair), FMS +1.4% (upgraded to Buy from Hold at Berenberg), BDN +0.9% (upgraded to Buy from Hold at Stifel), DLR +0.7% (upgraded to Mkt Perform from Underperform at Cowen)